File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation

TitleSafety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation
Authors
Issue Date2007
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 2007, v. 39 n. 11, p. 661-665 How to Cite?
AbstractReactivation of varicella zoster virus (VZV), clinically manifested as herpes zoster (HZ) is a common complication after hematopoietic stem cell transplantation (HSCT). The optimum prophylaxis for this disease has not been defined. In this study, we examined the effects of vaccinating donors with a live-attenuated vaccine with particular reference to their immune responses and the outcome of HSCT patients. Forty prospective HLA-matched sibling donors were vaccinated before HSCT. There were humoral immune responses in both sero-positive (P < 0.01) and sero-negative (P = 0.058) donors. Cellular immune response was assayed in 26 donors. Significant correlation was observed between cellular immune responses as enumerated by thymidine incorporation and interferon γ secretion (P < 0.001) and the latter was used in subsequent analyses. Significant response was observed in sero-negative (6/26) and a group of sero-positive (13/26) donors while 7/26 sero-positive donors showed no response. Thirty-four HSCT were performed. These patients have a lower, albeit insignificant, risk of HZ compared with historical controls and only 3/34 patients developed single dermatomal HZ at 6, 9 and 28 months after HSCT. No patients developed VZV-related mortality. Vaccinating donors with live-attenuated VZV vaccine was safe, but whether it confers a significant protection to the patients would require further study.
Persistent Identifierhttp://hdl.handle.net/10722/163084
ISSN
2015 Impact Factor: 3.636
2015 SCImago Journal Rankings: 1.585
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, AYHen_US
dc.contributor.authorChow, HCHen_US
dc.contributor.authorKwok, JSYen_US
dc.contributor.authorLui, CKHen_US
dc.contributor.authorCheng, VCCen_US
dc.contributor.authorYuen, KYen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLiang, Ren_US
dc.date.accessioned2012-09-05T05:27:24Z-
dc.date.available2012-09-05T05:27:24Z-
dc.date.issued2007en_US
dc.identifier.citationBone Marrow Transplantation, 2007, v. 39 n. 11, p. 661-665en_US
dc.identifier.issn0268-3369en_US
dc.identifier.urihttp://hdl.handle.net/10722/163084-
dc.description.abstractReactivation of varicella zoster virus (VZV), clinically manifested as herpes zoster (HZ) is a common complication after hematopoietic stem cell transplantation (HSCT). The optimum prophylaxis for this disease has not been defined. In this study, we examined the effects of vaccinating donors with a live-attenuated vaccine with particular reference to their immune responses and the outcome of HSCT patients. Forty prospective HLA-matched sibling donors were vaccinated before HSCT. There were humoral immune responses in both sero-positive (P < 0.01) and sero-negative (P = 0.058) donors. Cellular immune response was assayed in 26 donors. Significant correlation was observed between cellular immune responses as enumerated by thymidine incorporation and interferon γ secretion (P < 0.001) and the latter was used in subsequent analyses. Significant response was observed in sero-negative (6/26) and a group of sero-positive (13/26) donors while 7/26 sero-positive donors showed no response. Thirty-four HSCT were performed. These patients have a lower, albeit insignificant, risk of HZ compared with historical controls and only 3/34 patients developed single dermatomal HZ at 6, 9 and 28 months after HSCT. No patients developed VZV-related mortality. Vaccinating donors with live-attenuated VZV vaccine was safe, but whether it confers a significant protection to the patients would require further study.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshChickenpox Vaccine - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHematopoietic Stem Cell Transplantation - Methodsen_US
dc.subject.meshHerpes Zoster - Prevention & Controlen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshSafetyen_US
dc.subject.meshSiblingsen_US
dc.subject.meshTissue Donorsen_US
dc.subject.meshTransplantation, Homologousen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleSafety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantationen_US
dc.typeArticleen_US
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLeung, AYH=rp00265en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.bmt.1705673en_US
dc.identifier.pmid17417658-
dc.identifier.scopuseid_2-s2.0-34249313365en_US
dc.identifier.hkuros132732-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34249313365&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume39en_US
dc.identifier.issue11en_US
dc.identifier.spage661en_US
dc.identifier.epage665en_US
dc.identifier.isiWOS:000246560800002-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLeung, AYH=7403012668en_US
dc.identifier.scopusauthoridChow, HCH=7102303391en_US
dc.identifier.scopusauthoridKwok, JSY=7006208874en_US
dc.identifier.scopusauthoridLui, CKH=16319214100en_US
dc.identifier.scopusauthoridCheng, VCC=23670479400en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.citeulike1218384-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats